Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT05977088
Recruiting Not applicable

Prediction of Effectiveness of rTMS Application in Alzheimer's Patients

NCT05977088 · tracked via the Priya Life Science Turkey tracker
Sponsor
Istanbul Medipol University Hospital
Phase
Not applicable
Started
2022-02-16
Last updated
2025-05-02

Condition(s) studied

Alzheimer Disease

Investigational drug(s) / intervention(s)

Repetetive Transcranial Magnetic Stimulation

Repetetive Transcranial Magnetic Stimulation: .Power Mag TMS device will be used throughout the study, and the excitations will be made with the help of an 8 shaped coil (diameter: 70 mm) with internal cooling. The right-left DLPFC, which is the application area, will be determined with the help of the primary motor hand area and the 10/20 EEG system. A resting state EEG (eyes open-closed) will be taken in the Faraday cage. The same procedures will be done with the sham coil in the control group.

Study summary

Since pharmacological methods are insufficient in the treatment processes of Alzheimer's disease, non-pharmacological methods such as Transcranial Magnetic Stimulation (TMS) have started to be tried as a treatment option as in other neurological and psychiatric diseases. Repeated (rTMS) offers a potential treatment pathway for neurological and psychiatric illnesses. rTMS benefit rate may vary depending on many factors such as the region where it is applied, the progression and the disease degree. The possible effects of TMS on Alzheimer's pathophysiology and modification of disease process (neuroprotective, anti-inflammatory and antioxidant) will also be revealed through blood samples taken from patients before and after treatment. These approaches also constitute the original value of our study.

Eligibility

Sex
ALL
Min age
55 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Have been diagnosed with clinical Alzheimer's Disease in accordance with the NINCDS-ADRDA diagnostic criteria * \>55 years old * Clinical Dementia Rating Scale (CDR) score in the 1-2 range * Not having any other disease that affects their cognitive functions * Volunteer to participate in the study Exclusion Criteria: * Participant or relative does not give consent * The patient's inability to participate in the entire study procedure (eg living in another city) * The patient's history of head trauma with alcohol/substance abuse * Presence of severe stroke and other neurological sequelae disease in the participant * Presence of a metal implant on the head or having a pacemaker and contraindications for other TMS applications During the study or 1 month before, having/been receiving/receiving an investigational drug targeting Alzheimer's disease or neuromodulation treatment such as tDCS and TMS, other than standard treatment for AD symptom control such as acetylcholine esterase and memantine, with the potential to affect the study

Primary outcome measure(s)

  • The Mini Mental State Examination — Changes Before Treatment and 1 month after treatment
    Cognitive Neuropsychological Test Score
  • Neuropsychiatric Inventory — Changes Before Treatment and 1 month after treatment
    Cognitive Neuropsychological Test Score
  • Alzheimer's Disease Assessment Scale — Changes Before Treatment and 1 month after treatment
    Cognitive Neuropsychological Test Score
  • ADSL — Changes Before Treatment and 1 month after treatment
    Cognitive Neuropsychological Test Score
  • Geriatric Depression Scale — Changes Before Treatment and 1 month after treatment
    Cognitive Neuropsychological Test Score

Trial sites (1)

FacilityCityRegionStatus
Medipol University Hospital Istanbul Turkey (Türkiye) Recruiting

More Istanbul Medipol University Hospital trials in Turkey

Paraffin Oil for Preventing Tourniquet-Related Skin Lesions in Upper Extremity Surgery Recruiting
Comparison of PR Efficiency in Home-based With Hospital-based PR in Bronchiectasis Recruiting
Quadro-Iliac Plane Block for Pain Control After Posterior Spinal Instrumentation Surgery Starting soon
IASTM Effects on Pain, Functionality, and Proprioception in Subacromial Impingement Recruiting
Mechanical Properties of Peripheral and Accessory Respiratory Muscles in Chronic Obstructive Pulmonary Disease Patients Recruiting

Other trials for the same condition

Effect of Art Therapy on Cognitive and Hand Functions of Alzheimer's Patients Starting soon
The Effects of Specific tDCS on Cognition in MCI Recruiting
Semantic Recognition Task (SRT) in Alzheimer Disease Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) Recruiting
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05977088 on ClinicalTrials.gov ↗ ← All trials in Turkey